We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Methylation Generates Differential Gene Expression in Sister Stem Cells

By LabMedica International staff writers
Posted on 14 Oct 2013
DNA methylation was shown to be primarily responsible for differences in gene expression displayed by "sister" stem cells.

Despite having identical DNA, sister embryonic stem cells (ESCs) can display considerable differences in their molecular characteristics. More...
How stem cells regulate expression of their genes is crucial to many fundamental biological processes, such as embryonic development, regeneration, and turnover of blood, skin, and other tissues in the body, but especially to cancer.

In a study published in the September 26, 2013, online edition of the journal Stem Cell Reports investigators at the Institute of Cancer Research (London, United Kingdom) used a novel microdissection technique to examine differences in expression of 48 key genes between sister stem cells.

Their system, which was based on single cell RNA analysis, revealed considerable diversities between sister ESCs at both pluripotent and differentiated states. When the stem cells were grown in the presence inhibitors that induced the cells to revert to their most primitive stem cell state, gene expression between sister cells was significantly more similar.

DNA methyltransferases were downregulated in the inhibited ESCs, and the loss of these enzymes was sufficient to generate nearly identical sister cells. These results suggest that DNA methylation was a major cause of the diversity between sister cells at the pluripotent states. DNA methylation stably alters the expression of genes in cells as they divide and differentiate from embryonic stem cells into specific tissues. The resulting change is normally permanent and unidirectional, preventing a differentiated cell from reverting back to a stem cell or converting into another type of tissue.

Senior author Dr. Tomoyuki Sawado, leader of the stem cells and chromatin team at The Institute of Cancer Research, said, "Embryonic stem cell division is generally believed to be a symmetrical process, but what we found was that sister cells are actually often quite different from one another. We used a new technique to separate paired stem cells combined with assays that measure RNA in individual cells. Our research showed that sister stem cells display considerable differences in which genes are expressed. These differences are advantageous for normal stem cells in their constantly changing environment, and in cancer cells, the same characteristics can enable them to evade treatments. If we can control a process like DNA methylation that creates diversity in cell populations, we could create more efficient treatments for cancer."

Related Links:

The Institute of Cancer Research



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.